Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis: Interim data from OPAL Balance, an open label, long-term extension study - 11/08/17
Doi : 10.1016/j.jaad.2017.04.875
Le texte complet de cet article est disponible en PDF.
Peter Nash, MD, University of Queensland; Laura C Coates, PhD, University of Leeds; Alan J Kivitz, MD, Altoona Center for Clinical Research; Philip J Mease, MD, Swedish Medical Center and University of Washington; Dafna D Gladman, MD, University of Toronto; Jose A Covarrubias-Cobos, MD, Unidad Rheumatologica Las Americas S.C.P.; Elizabeth Kudlacz, PhD, Pfizer Inc; Sujatha Menon, PhD, Pfizer Inc; Keith S Kanik, MD, Pfizer Inc
Le texte complet de cet article est disponible en PDF.| Commercial support: This study was sponsored by Pfizer Inc. Medical writing support was provided under direction from the authors by Amanda Pedder of Complete Medical Communications and funded by Pfizer Inc. |
© 2017
Publié par Elsevier Masson SAS.
Vol 76 - N° 6S1
P. AB224 - juin 2017 Retour au numéro
Article précédent
- Safety and efficacy of multiple ascending doses of subcutaneous M1095, an anti-interleukin-17A/F bispecific nanobody, in patients with moderate-to-severe psoriasis
- Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: Statistical metaanalysis of pooled data from global registration studies of treatment of crow’s feet lines and glabellar lines in more than 3900 participants
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?